These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
644 related articles for article (PubMed ID: 34704283)
21. A case report of successful transition from argatroban to warfarin using DOAC-stop in heparin induced thrombocytopenia (HIT). Makhija K; Chapman K; Prasad R Pathology; 2021 Oct; 53(6):800-802. PubMed ID: 33610318 [No Abstract] [Full Text] [Related]
22. Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement? Samoš M; Bolek T; Škorňová I; Benko J; Staško J; Kubisz P; Galajda P; Mokán M J Thromb Thrombolysis; 2019 Nov; 48(4):619-622. PubMed ID: 31264059 [TBL] [Abstract][Full Text] [Related]
23. Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current Experiences. Samoš M; Bolek T; Ivanková J; Stančiaková L; Kovář F; Galajda P; Kubisz P; Staško J; Mokáň M J Cardiovasc Pharmacol; 2016 Nov; 68(5):391-394. PubMed ID: 27464495 [TBL] [Abstract][Full Text] [Related]
25. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Saugel B; Phillip V; Moessmer G; Schmid RM; Huber W Crit Care; 2010; 14(3):R90. PubMed ID: 20487559 [TBL] [Abstract][Full Text] [Related]
26. [Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)]. Delgado-García G; Monreal-Robles R; Gallegos-Arguijo D; Marfil-Rivera J Gac Med Mex; 2015; 151(6):798-801. PubMed ID: 26581538 [TBL] [Abstract][Full Text] [Related]
27. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Lewis BE; Wallis DE; Hursting MJ; Levine RL; Leya F Chest; 2006 Jun; 129(6):1407-16. PubMed ID: 16778256 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban. Dreucean D; Nguyen SN; Donahue KR; Salazar E; Ruegger MC J Thromb Thrombolysis; 2021 Jul; 52(1):161-169. PubMed ID: 33099722 [TBL] [Abstract][Full Text] [Related]
29. Direct oral anticoagulants in hypercoagulable states. Kunk PR; Brown J; McShane M; Palkimas S; Gail Macik B J Thromb Thrombolysis; 2017 Jan; 43(1):79-85. PubMed ID: 27632140 [TBL] [Abstract][Full Text] [Related]
30. How we manage patients with heparin induced thrombocytopenia. Scully M; Gates C; Neave L Br J Haematol; 2016 Jul; 174(1):9-15. PubMed ID: 27097741 [TBL] [Abstract][Full Text] [Related]
31. Heparin-Calibrated Anti-Factor Xa Assay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and Edoxaban. Ahn HS; Chae H; Kim Y; Lee HK; Kim H Clin Lab; 2024 Sep; 70(9):. PubMed ID: 39257123 [TBL] [Abstract][Full Text] [Related]
32. A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia. Davis K; Sebaaly J; Wooten L; Khouli C; Mihm A; Nisly SA Am J Cardiovasc Drugs; 2022 Jul; 22(4):417-424. PubMed ID: 35040095 [TBL] [Abstract][Full Text] [Related]
33. Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study. Fisser C; Winkler M; Malfertheiner MV; Philipp A; Foltan M; Lunz D; Zeman F; Maier LS; Lubnow M; Müller T Crit Care; 2021 Apr; 25(1):160. PubMed ID: 33910609 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban in treatment refractory heparin-induced thrombocytopenia. Casan JM; Grigoriadis G; Chan N; Chunilal S BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27520997 [TBL] [Abstract][Full Text] [Related]
36. Apixaban and rivaroxaban in patients with cerebral venous thrombosis. Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600 [No Abstract] [Full Text] [Related]
37. [From heparin to apixaban: anticoagulants cut both ways?]. Hartung K; Meyer F; Bock F; Isermann B Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104 [TBL] [Abstract][Full Text] [Related]
38. Novel oral anticoagulants for heparin-induced thrombocytopenia. Skelley JW; Kyle JA; Roberts RA J Thromb Thrombolysis; 2016 Aug; 42(2):172-8. PubMed ID: 27102287 [TBL] [Abstract][Full Text] [Related]
39. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator. Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443 [TBL] [Abstract][Full Text] [Related]
40. New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review. Dhakal P; Pathak R; Giri S; Murthy GS; Bhatt VR Cardiovasc Hematol Agents Med Chem; 2015; 13(2):87-91. PubMed ID: 26695419 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]